Nasdaq · Healthcare
Indivior Pharmaceuticals, Inc. (INDV)
As-reported financials and recent SEC filings for Indivior Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.24B
Net income
$210.0M
Net margin
16.9%
Diluted EPS
$1.64
ROE
-214.3%
P/E (TTM)
21.5×
Market cap
$4.94B
Debt / equity
-3.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.0M | — |
| Gross profit | $993.0M | $957.0M | $919.0M | $750.0M | — |
| Operating income | $262.0M | $38.0M | $-152.0M | $-81.0M | — |
| Net income | $210.0M | $7.0M | $-126.0M | $-44.0M | — |
| Diluted EPS | $1.64 | $0.05 | $-0.92 | $-0.32 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-10
View on EDGAR →144/A2026-06-08
View on EDGAR →1442026-06-08
View on EDGAR →8-K2026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →Go deeper on INDV
Search Indivior Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.